Drug intelligence / Profile preview

CASI-001

Development stage: Preclinical
Lead developer: CASI Pharmaceuticals

Overview

CASI-001 is a proprietary early-stage immuno-oncology drug candidate developed by CASI Pharmaceuticals. As of 2018, the asset was in preclinical development alongside CASI-002. While categorized within the immuno-oncology space, specific details regarding its biological target, molecular modality (e.g., small molecule vs. monoclonal antibody), and primary disease indications have not been publicly disclosed in available company pipelines or clinical literature.

Beyond the preview

Go deeper on CASI-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CASI-001.

Explore the full profile